Oncolytics Biotech Inc. (ONCY)
NASDAQ: ONCY · IEX Real-Time Price · USD
0.990
-0.005 (-0.52%)
At close: Jul 2, 2024, 4:00 PM
1.020
+0.030 (3.03%)
After-hours: Jul 2, 2024, 6:01 PM EDT
Oncolytics Biotech Stock Forecast
Stock Price Forecast
The 2 analysts with 12-month price forecasts for Oncolytics Biotech stock have an average target of 4.00, with a low estimate of 3.00 and a high estimate of 5.00. The average target predicts an increase of 304.04% from the current stock price of 0.99.
Analyst Consensus: Strong Buy
* Price targets were last updated on May 14, 2024.
Analyst Ratings
The average analyst rating for ONCY stock from 2 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
Rating | Jan '24 | Feb '24 | Mar '24 | Apr '24 | May '24 | Jun '24 |
---|---|---|---|---|---|---|
Strong Buy | 3 | 3 | 3 | 3 | 3 | 1 |
Buy | 0 | 0 | 0 | 1 | 1 | 1 |
Hold | 0 | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 3 | 3 | 3 | 4 | 4 | 2 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $5 | Strong Buy | Reiterates | $5 | +405.05% | May 14, 2024 |
Raymond James | Raymond James | Buy Initiates $3 | Buy | Initiates | $3 | +203.03% | Apr 4, 2024 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $5 | Strong Buy | Maintains | $5 | +405.05% | Mar 8, 2024 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $5 | Strong Buy | Reiterates | $5 | +405.05% | Feb 14, 2024 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $5 | Strong Buy | Reiterates | $5 | +405.05% | Jan 19, 2024 |
Financial Forecast
Revenue This Year
1.21M
Revenue Next Year
10.08M
from 1.21M
Increased by 731.35%
EPS This Year
-0.40
from -0.41
EPS Next Year
-0.37
from -0.40
Revenue Forecast
Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | 6.3M | 41.9M | 139.3M | 212.8M | 433.3M |
Avg | 1.2M | 10.1M | 44.7M | 79.1M | 202.3M |
Low | n/a | n/a | n/a | n/a | 21.5M |
Revenue Growth
Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | - | 3,357.3% | 1,282.5% | 376.5% | 447.6% |
Avg | - | 731.4% | 343.3% | 77.2% | 155.7% |
Low | - | - | - | - | -72.9% |
EPS Forecast
EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | -0.37 | -0.14 | 0.82 | 1.48 | 2.66 |
Avg | -0.40 | -0.37 | -0.03 | 0.18 | 0.69 |
Low | -0.50 | -0.45 | -0.45 | -0.43 | -0.30 |
EPS Growth
EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | - | - | - | - | 1,341.4% |
Avg | - | - | - | - | 274.4% |
Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.